MedTrace Logo

Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients

NCT00879996 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2012-08-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if buprenorphine or methadone is better for the treatment of chronic pain among patients who have become addicted to prescription narcotics.

Conditions

  • Opiate Addiction

Interventions

DRUG

Methadone

Oral, 10-60 mg per day, 2-4 times per day, 6 months

DRUG

Buprenorphine/naloxone

Sub-lingual, 4-16 mg per day, divided 2-4 times/day, 6 months

Sponsors & Collaborators

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    collaborator NIH

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • State University of New York at Buffalo

    lead OTHER

Principal Investigators

  • Richard D Blondell, MD · SUNY Buffalo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00879996 on ClinicalTrials.gov